| WB | 咨询技术 | Mouse,Rat |
| IF | 1/20-1/50 | Mouse,Rat |
| IHC | 1/100-1/200 | Mouse,Rat |
| ICC | 技术咨询 | Mouse,Rat |
| FCM | 咨询技术 | Mouse,Rat |
| Elisa | 咨询技术 | Mouse,Rat |
| Aliases | API4;Apoptosis inhibitor survivin;BIRC 5;EPR 1;IAP4;SVV;TIAP;Survivin |
| WB Predicted band size | 16 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse,Rat |
| Immunogen | A synthesized peptide derived from mouse Survivin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Survivin抗体的3篇参考文献及其摘要内容：
---
1. **文献名称**：*"Survivin: A novel target for cancer therapy"*
**作者**：Altieri, D.C.
**摘要**：该研究系统评估了不同Survivin抗体的特异性和应用场景，通过Western blot和免疫沉淀技术验证了抗体在多种癌细胞系中的结合效率，并强调了抗体选择对实验可靠性的影响。
2. **文献名称**：*"Immunohistochemical analysis of Survivin expression in human colorectal carcinomas"*
**作者**：Kawasaki, H., et al.
**摘要**：研究利用特异性Survivin抗体对结直肠癌组织进行免疫组化分析，发现Survivin高表达与患者不良预后显著相关，验证了该抗体在临床病理诊断中的潜在价值。
3. **文献名称**：*"Targeting Survivin with monoclonal antibodies in cancer therapy"*
**作者**：Pennati, M., et al.
**摘要**：该研究开发了一种新型Survivin单克隆抗体，并在体外和小鼠模型中证实其能有效抑制肿瘤生长并诱导凋亡，为靶向Survivin的抗体药物研发提供了实验依据。
---
以上文献涵盖了Survivin抗体的基础验证、临床诊断应用及治疗开发方向，可作为相关研究的参考。如需更近期研究，建议在PubMed或Web of Science中检索关键词“Survivin antibody”并筛选高被引论文。
Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is a critical regulator of cell division and apoptosis. It is uniquely overexpressed in most human cancers but minimally detected in normal adult tissues, making it a promising therapeutic and diagnostic target. Survivin antibodies are immunodetection tools designed to recognize and bind Survivin in experimental or clinical samples. These antibodies play a key role in studying Survivin's functions, including its dual role in inhibiting caspase activity to block apoptosis and regulating mitosis through interactions with microtubules.
In research, Survivin antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to assess protein expression levels, subcellular localization, and correlation with cancer progression or treatment resistance. Clinically, they serve as potential biomarkers for cancer diagnosis, prognosis, and therapeutic monitoring. High Survivin expression often correlates with aggressive tumor behavior, poor survival rates, and chemotherapy resistance.
The development of Survivin-specific antibodies faces challenges, including cross-reactivity with homologous proteins (e.g., other IAPs) and ensuring consistent performance across sample types. Recent advances focus on optimizing antibody specificity for Survivin's unique BIR domain or dimerization interfaces. Additionally, Survivin-targeting antibodies are being explored for therapeutic applications, such as antibody-drug conjugates or immune checkpoint modulators. Their clinical utility is under investigation in combination therapies aiming to overcome conventional treatment resistance in oncology.
×
